SARCOMA

The target number of patients with soft tissue sarcoma lung metastases have been enrolled in the phase 1b/2 study of Annamycin, commencing the recruiting portion of the trial.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.

Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).

Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).

An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.

Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.

Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.

Experts in the field of gastrointestinal stromal tumors (GISTs) discuss the role of sequencing therapy in the frontline and later-line settings.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

The FDA has granted fast track designation to Annamycin for the treatment of soft tissue sarcoma lung metastases, according to a press release from Moleculin Biotech, Inc.

In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.

An Orphan Drug Designation was granted by the FDA to ilixadencel as use for the treatment of patients with soft tissue sarcoma.

The FDA has granted an Orphan Drug Designation to annamycin for the treatment of patients with soft tissue sarcomas.

In an interview with Targeted Oncology, Michael J. Wagner, MD, discussed findings from a single-center experience in Seattle managing patients with sarcoma during the COVID-19 pandemic.

The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.

Selinexor induced a statistically significant reduction in the risk of disease progression or death compared with placebo as treatment of patients with advanced unresectable dedifferentiated liposarcoma.

The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.